Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Harlingene Life Sciences LLC
Profile last edited on: 2/26/24      CAGE: 8WTD2      UEI: VWGYKR56KRU3

Business Identifier: Development of small molecule therapeutics for liver diseases
Year Founded
2021
First Award
2022
Latest Award
2023
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

3805 Old Easton Road
Doylestown, PA 18902
   (646) 209-8525
   N/A
   N/A
Location: Single
Congr. District: 01
County: Bucks

Public Profile

A biotech spin-out from the Baruch S. Blumberg Institute, Harlingene Life Sciences LLC is structured around the development of small molecule therapeutics for liver diseases to address important unmet medical needs

Extent of SBIR involvement

User Avatar
Phase I Awards
2
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$600,000
Phase II Dollars
$0
Total Awarded
$600,000

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2024 2 NIH $600,000
Project Title: Hepatoselective Dihydroquinolizinone (HS-DHQ) Molecules for Treatment and Prevention of Hepatitis a Virus (HAV) Infection
2022 1 NIH $300,000
Project Title: Developing Hepatoselective Hepatitis B Therapeutic Dihydroquinolizinone (DHQ) Molecules with Better Safety Profiles for Efficient HBsAg Reduction

Key People / Management

  Timothy M Block -- CEO

  Yanming Du -- Chief Scienti\iifc Officer

  Brian Eves -- President

  Louis P Kassa III -- Chief Business Officer

Company News

There are no news available.